Lux Capital is a stage-agnostic venture firm focused on frontier science and deep technology, investing globally from first experiments through growth rounds. The firm is known for high-conviction bets on technically difficult, non-consensus companies in areas like defense, AI, biotech, aerospace, and industrial systems—backing founders who can turn "sci-fi into sci-fact."
Evaluation weights
How much weight this firm places on each dimension. Totals 100%.
Revenue, growth, and unit economics
Size, timing, and competitive landscape
Founder experience and execution ability
Differentiation and technical quality
- Strong bias toward technical depth over early commercial polish
- Willingness to underwrite technology risk when the team is exceptional
- Preference for non-consensus categories rather than consensus momentum trades
- More receptive to hard-tech, dual-use, and science-heavy businesses than most generalist VCs
Pitch difficulty
How hard it is to get a meeting and close funding from this firm.
- Funded / yr
- 67Deals closed in a typical year.
- Led / yr
- 14Rounds led in the last 12 months.
- Pitches / yr
- ~2912Decks reviewed in a typical year.
- Acceptance rate
- 2.3%Share of pitches that get funded.
Estimated — public data is not fully disclosed.
Why it's hard
- Focus on rare, technically elite founders in difficult domains
- Preference for non-incremental companies with hard scientific or engineering moats
- High-conviction style means fewer but deeper bets
- Strong bias toward category-defining outcomes in massive frontier markets
Lux is highly selective because it targets a narrow set of founder and company profiles: exceptional technical teams building breakthrough deep-tech businesses with potential for category-defining outcomes. Its broad stage range and large check flexibility increase relevance, but the bar for technical originality, ambition, and founder-market fit is unusually high.
Green flags
What drives a yes for this firm.
- A rare technical moat rooted in real science or engineering advantage
- Founders with exceptional domain credibility, often deeply technical specialists
- A non-consensus thesis in a market others may misunderstand or undervalue
- Potential to become foundational infrastructure or a category-defining platform
- Evidence that compute, automation, or biology creates asymmetric leverage
Red flags
What kills deals and gets a fast no.
- Incremental products in crowded markets without a hard technical edge
- Founders lacking deep domain credibility in highly technical categories
- AI or biotech narratives that are mostly hype and light on proprietary substance
- No clear path from research novelty to real-world deployment or commercialization
- Small-market opportunities that cannot justify Lux's ambition and conviction
How to win
Patterns that lead to successful pitches.
- Lead with the breakthrough: explain the technical moat in concrete scientific or engineering terms
- Show why this team is uniquely qualified to solve the problem, not just interested in it
- Frame the opportunity as a non-consensus but massive market that could become critical infrastructure
- Present milestone evidence that de-risks the core science, even if revenue is still minimal
- Demonstrate a credible path from frontier technology to a durable platform business
Fund strategy & identity
Who they are and how they operate.
- Invest across the full company lifecycle, from pre-revenue formation to large growth rounds
- Back companies with hard technical moats in science, engineering, biology, and compute
- Lead rounds aggressively with flexible check sizes from small seed checks to very large financings
- Favor misunderstood or nascent markets over crowded, incremental categories
- Support category creation where breakthrough technology can become critical infrastructure
Firm identity
Investment focus
Industries, themes, and typical ARR expectations.
Industries
Investment themes
Typical check by stage
Typical ARR by stage
Investment thesis
Core beliefs and strategy behind their investing approach.
Lux Capital backs frontier science and technology across sectors such as aerospace, biotechnology, defense and national security, industrial automation, transportation, data & AI, sensing, and related deep‑tech domains. Their core belief is turning "sci‑fi into sci‑fact" by partnering with founders who have rare technical expertise and are tackling problems where compute, automation, or biology can generate asymmetrical advantages. Lux is stage‑agnostic, deploying checks from $100 K up to $100 M and staying invested from the earliest experiments through large growth rounds. Geographically, the firm is global, anchored in New York with a Silicon Valley office, and it invests in companies worldwide. While it does not publish a formal anti‑thesis, Lux avoids overly crowded, incremental markets lacking a hard technical edge, focusing instead on non‑consensus categories where markets are misunderstood or nascent. This thesis drives a long‑term partnership model that treats capital as a tool to scale breakthrough science into enduring businesses.
Decision patterns
How they evaluate and make investment decisions.
Lux invests when a startup demonstrates a deep technical moat and is led by founders with rare domain expertise—often PhDs or seasoned engineers—pursuing hard problems where compute, automation, or biology create asymmetry. The firm favors non‑consensus theses and technologies that could become critical infrastructure, such as national‑security AI platforms or novel therapeutics. In evaluating deals, Lux places the team and technology above early market traction; at seed stage it will back pre‑product, pre‑revenue companies based on scientific merit, while later stages require clear productization, strategic contracts, or milestone achievements. Deal‑breakers include incremental offerings lacking a hard technical edge, overly crowded markets, and weak founder‑market fit in highly technical domains.
Risk appetite
Lux Capital exhibits an aggressive, conviction‑driven risk appetite. The firm regularly leads rounds—from seed checks of $100 K to massive $100 M investments—showing comfort with pre‑revenue, pre‑product companies, especially in frontier AI, defense, and biotech. Its stage‑agnostic mandate and willingness to commit large capital when it believes in a technology’s long‑term impact place it on the aggressive side of the risk spectrum, favoring lead positions over passive follow‑on investments.
Notable investments
Key portfolio companies and why they fit the thesis.
- Hugging FaceLeadOpen–source NLP platform core to the AI ecosystem, matching Lux’s AI/infra frontier thesis.
- MatterportLead3D capture of the built world combines computer vision and hardware at scale, fitting Lux’s deep–tech focus.
- Auris HealthLeadTransformational surgical–robotics company at the intersection of AI and biotech, aligned with Lux’s health–tech frontier agenda.
- HadrianLeadAutonomous, software–defined factories for precision defense/space components, exemplifying Lux’s industrial–automation thesis.
- Applied IntuitionLeadVehicle–intelligence and autonomy tooling that brings AI software into large–scale automotive and aerospace markets.
- OsmoLeadAI–powered fragrance design merges machine learning with chemistry, a novel frontier application of AI.
- KallyopeLeadPlatform biotech unlocking the gut–brain axis, reflecting Lux’s science–driven biotech investments.
- BenchlingLife–sciences R&D cloud provides data infrastructure for biotech, fitting Lux’s health–tech interest.
- RunwayNext–gen creative AI tools align with Lux’s support for frontier AI applications.
- DatabricksCore data–plus–AI platform that backs many of Lux’s AI–focused investments.
Co-invested with
Other firms in this catalog who've backed the same companies.
Partners
Full firm roster — key partners, partners, and the wider team.
Key partners
Josh Wolfe
Partner and Co-Founder
Lux Capital
Josh Wolfe is Partner and Co-Founder at Lux Capital. His official profile says he helps lead the firm, invests in defense and biotech, and has co-founded more than 20 Lux companies.
Peter Hébert
Partner and Co-Founder
Lux Capital
Peter Hébert is Partner and Co-Founder at Lux Capital. His official profile says he helps lead the firm, invests across technology and healthcare, and launched Lux's Health + Tech investment strategy.
Shahin Farshchi, PhD
Partner
Lux Capital
Shahin Farshchi is a Partner at Lux Capital. His official profile describes more than two decades partnering with frontier-technology founders and investments spanning AI, semiconductors, autonomy, and aerospace.
Deena Shakir
Partner
Lux Capital
Deena Shakir is a Partner at Lux Capital. Her official profile says she invests across stages and sectors, including women's health, digital health infrastructure, health equity, foodtech, and fintech.
Bilal Zuberi
Co-President & General Partner
Lux Capital
Bilal Zuberi is associated with Lux Capital as a long-time deeptech investor. Public profiles describe more than a decade as a Lux General Partner, with investments across applied AI, autonomy, industrial technology, hardware, climate, healthcare and other technically ambitious sectors.
Partners
Danny Crichton
Partner, Research
Lux Capital
Lux Partner, Research and editor-in-chief, formerly managing editor at TechCrunch.
David K. Yang
Partner
Lux Capital
Lux life sciences partner focused on therapeutics, R&D tools and biopharma infrastructure.
Lan Jiang
Partner
Lux Capital
Lux partner focused on biotech analytics, ML infrastructure, developer tooling, and AI applications.
Laurence Pevsner
Partner, Research
Lux Capital
Lux research partner focused on media, pedagogy, Riskgaming, and science-policy communication.
Brandon Reeves
Partner
Lux Capital
Lux partner investing in AI, software, defense, manufacturing and robotics.
Grace Isford
Partner
Lux Capital
Lux partner investing in computational sciences, AI applications, and infrastructure software.
Tracie Rotter
Partner, Platform
Lux Capital
Lux platform partner connecting portfolio companies with customers, talent, and strategic partners.
Shaquille Vayda
Partner
Lux Capital
Lux partner backing deeply technical platform companies across physical, life, and computational sciences.
Robert Paull
Co-Founder and Venture Partner
Lux Capital
Lux co-founder and healthcare venture partner with biotech CEO and company-formation experience.
Public voice
Notable statements and public positions.
- "We believe before others understand."
- "Some firms don’t take technology risk. I don’t think they should call themselves venture capitalists… The best definition of risk is that more things can happen than will."
- "For these businesses and founders to become category‑defining winners, they need meaningful capital and conviction… a $1.5B commitment to investing in the people turning sci‑fi into sci‑fact."
Similar firms
Firms with overlapping stage and industry focus.
Qualcomm Ventures
0.3%
Andreessen Horowitz
0.5%
Founders Fund
1.5%